SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology FRESH-PEF73865-en Elodie MORILLAND-LECOQ SFCE national cohort on SARS-CoV-2 (COVID-19) infections in paediatric oncology-haematology PEDONCOVID FRESH-PEF73865-en 73865 FRESH-PEF73865 Jérémie ROUGER-GAUDICHON CENTRE HOSPITALIER UNIVERSITAIRE DE CAEN NORMANDIE (CHU) Epidemiology France Portal (PEF) null cancer paediatrics chemotherapy SARS-CoV-2 COVID-19 Paediatrics Neoplasms COVID-19 Describe the presentation and clinical course of SARS-CoV-2 infection among patients followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre, for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy. null France Individuals Patients population Male Female Infant, Newborn (birth to 28 days) Infant (28 days to 2 years) Child, Preschool (2 to 5 years) Child (6 to 12 years) Children and legal representatives, or adult patients having received information on the study AND - Patient followed up in a paediatric oncology-haematology department or young adult and adolescent unit at an SFCE centre for cancer or a benign tumour treated with chemotherapy, radiotherapy or targeted therapy, with a cancer treatment either ongoing or completed within the past 6 months, or a history of allogeneic haematopoietic stem cell transplantation with immunosuppressant therapy ongoing or discontinued within the past 6 months, or a history of CAR-T cell therapy AND - Diagnosis of SARS-CoV-2 infection confirmed by PCR or positive IgM serology OR - Clinical and radiological diagnosis characteristic of SARS-CoV-2 infection without confirmation of infection by PCR or positive IgM serology with: o Presence of at least 2 of the following signs in the event of contact with a subject currently presenting SARS-CoV-2 positive infection, or 3 of the following signs in the absence of contact: fever, cough, dysgeusia, dysosmia, myalgia, chest pain, dyspnoea, signs of respiratory distress, rhinorrhoea or nasopharyngeal congestion, diarrhoea, headaches, recent onset or exacerbation of asthenia and rash. AND o One or more radiological abnormalities observed on chest CT scan compatible with a diagnosis of COVID-19: peripheral and/or subpleural and/or bilateral ground-glass opacities, intralobular thickening with a “crazy-paving” appearance, linear condensations with or without peripheral halo (reverse halo sign). Clinical data Biological data Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Interview with the participant (including clinical) Observational Study Observational Study Cohort study Unknown To be defined